Scarica l'app Stockscreener
11.96
3.55%
0.41
Dopo l'orario di chiusura:
11.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$11.55
Aprire:
$11.75
Volume 24 ore:
852.87K
Relative Volume:
0.40
Capitalizzazione di mercato:
$1.91B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-8.8593
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
+6.31%
1M Prestazione:
+42.89%
6M Prestazione:
+49.87%
1 anno Prestazione:
+48.57%
Intervallo 1D:
$11.74
$11.96
Intervallo di 1 settimana:
$11.23
$11.96
Portata 52W:
$5.80
$11.96
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Confronta OCUL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.96 | 1.84B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
What drives Ocular Therapeutix Inc. stock priceMassive wealth growth - Autocar Professional
Ocular Therapeutix stock hits 52-week high at $11.78 - Investing.com India
What analysts say about Ocular Therapeutix Inc. stockAccelerated wealth building - Autocar Professional
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire
Ocular Therapeutix Inc. Stock Analysis and ForecastRecord-breaking gains - jammulinksnews.com
Ocular Therapeutix Announces Participation in Upcoming Scientific Conferences Focused on Retina Innovation - Quiver Quantitative
Ocular Therapeutix Participates in Upcoming Scientific Conferences - AInvest
Ocular Therapeutix Unveils Breakthrough Diabetic Retinopathy Treatment Data Across 3 Major Eye Conferences - Stock Titan
Is Ocular Therapeutix Inc. a good long term investmentRemarkably fast returns - jammulinksnews.com
(OCUL) Trading Report - news.stocktradersdaily.com
FMR LLC's Strategic Acquisition of Ocular Therapeutix Shares: A Financial Analysis - AInvest
Ocular Therapeutix(OCUL) Soars 8.47% on Pipeline Progress - AInvest
Institutional investors control 65% of Ocular Therapeutix, Inc. (NASDAQ:OCUL) and were rewarded last week after stock increased 3.7% - simplywall.st
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) dropped from Russell 3000E Index - MarketScreener
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) dropped from Russell 3000E Growth Index - MarketScreener
Selling US$1.1m Of Ocular Therapeutix Stock Rewarded Insiders - 富途牛牛
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - The Manila Times
Ocular Therapeutix Launches New Corporate Branding to Enhance Retina-Focused Mission - Nasdaq
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Yahoo Finance
Pre-market Movers: NKTR, INM, IBIO, IBO... - RTTNews
OCUL SEC FilingsOcular Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Trend Tracker for (OCUL) - news.stocktradersdaily.com
Ocular Therapeutix to present at Clinical Trials at the Summit 2025 - Ophthalmology Times
Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years - Yahoo Finance
Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade) (OCUL) - Seeking Alpha
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 | OCUL Stock News - GuruFocus
Ocular Therapeutix, Inc. to Present Clinical Trial Results and Insights at Summit 2025 in Las Vegas - Nasdaq
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 - GlobeNewswire
Breakthrough Eye Disease Treatment Data: Ocular Therapeutix Reveals Clinical Trial Results at CTS 2025 - Stock Titan
Ocular Therapeutix Approves Key Amendments at Annual Meeting - TipRanks
Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology - insights.citeline.com
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 26% Jump Shows Its Popularity With Investors - simplywall.st
Trading (OCUL) With Integrated Risk Controls - news.stocktradersdaily.com
Ameriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Nuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
What is HC Wainwright’s Forecast for OCUL Q1 Earnings? - Defense World
Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN
Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at HC Wainwright - Defense World
Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus
Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga
Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):